Marker Therapeutics (NASDAQ:MRKR) Issues Quarterly Earnings Results, Beats Expectations By $0.17 EPS

Marker Therapeutics (NASDAQ:MRKR) released its earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.17, FiscalAI reports. The firm had revenue of $1.10 million during the quarter, compared to the consensus estimate of $0.68 million. Marker Therapeutics had a negative return on equity of 84.13% and a negative net margin of 343.03%.

Marker Therapeutics Stock Down 1.5%

MRKR opened at $1.32 on Friday. The firm has a market cap of $22.00 million, a PE ratio of -1.55 and a beta of 1.42. The business has a fifty day simple moving average of $1.60 and a 200-day simple moving average of $1.29. Marker Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $4.07.

Hedge Funds Weigh In On Marker Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in Marker Therapeutics during the 3rd quarter worth about $25,000. Two Sigma Investments LP acquired a new position in shares of Marker Therapeutics in the third quarter worth about $33,000. Jane Street Group LLC acquired a new position in shares of Marker Therapeutics in the second quarter worth about $33,000. XTX Topco Ltd increased its position in shares of Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after acquiring an additional 36,269 shares in the last quarter. Finally, LPL Financial LLC increased its position in shares of Marker Therapeutics by 41.7% in the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after acquiring an additional 24,500 shares in the last quarter. Institutional investors and hedge funds own 22.39% of the company’s stock.

Wall Street Analysts Forecast Growth

MRKR has been the subject of several research analyst reports. HC Wainwright initiated coverage on Marker Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective for the company. Wall Street Zen raised Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research report on Monday, December 8th. Zacks Research downgraded shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Marker Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.25.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.